F

Filament Health Corp
NEO:FH

Watchlist Manager
Filament Health Corp
NEO:FH
Watchlist
Price: 0.01 CAD -33.33% Market Closed
Market Cap: CA$2.6m

Filament Health Corp
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Filament Health Corp
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
F
Filament Health Corp
NEO:FH
Interest Income Expense
-CA$443.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Appili Therapeutics Inc
TSX:APLI
Interest Income Expense
-CA$3.8m
CAGR 3-Years
-36%
CAGR 5-Years
-229%
CAGR 10-Years
N/A
No Stocks Found

Filament Health Corp
Glance View

Market Cap
2.6m CAD
Industry
N/A

Filament Health Corp. is a Canada-based natural psychedelic drug discovery and development company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-06-24. The firm is engaged in natural extraction technologies utilizing patented and patent-pending processes to manufacture standardized, pharmaceutical grade psychoactive products. The firm operates through its Health Canada Dealer’s license at its good manufacturing practice (GMP) drug discovery and manufacturing facility. The Company’s subsidiary includes Psilo Scientific Ltd. (Psilo). Psilo is a drug discovery and extraction technologies company.

FH Intrinsic Value
Not Available
F

See Also

What is Filament Health Corp's Interest Income Expense?
Interest Income Expense
-443.5k CAD

Based on the financial report for Dec 31, 2023, Filament Health Corp's Interest Income Expense amounts to -443.5k CAD.

What is Filament Health Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-140%

Over the last year, the Interest Income Expense growth was -140%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett